Bispecific antibody therapies

2.

Tian

Z

,

Liu

M

,

Zhang

Y

,

Wang

X.

Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies

.

J Hematol OncolJ Hematol Oncol

.

2021

;

14

(

1

):

75

.

doi:10.1186/s13045-021-01084-4

.

3.

Ludwig

H

,

Terpos

E

,

van de Donk

N

, et al.

Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network

.

Lancet Oncol

.

2023

;

24

(

6

):

e255

-

e269

.

doi:10.1016/S1470-2045(23)00159-6

.

4.

Mohan

M

,

Chakraborty

R

,

Bal

S

, et al.

Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma

.

Br J Haematol

. Preprint. Published online

June

7

,

2023

.

doi:10.1111/bjh.18909

.

5.

Salvaris

R

,

Ong

J

,

Gregory

GP

.

Bispecific antibodies: a review of development, clinical efficacy and toxicity in B-cell lymphomas

.

J Pers Med

.

2021

;

11

(

5

):

355

.

doi:10.3390/jpm11050355

.

6.

Fielding

AK

,

Richards

SM

,

Chopra

R

, et al.

Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

.

Blood

.

2007

;

109

(

3

):

944

-

950

.

doi:10.1182/blood-2006-05-018192

.

7.

Mullard

A.

FDA approves first bispecific

.

Nat Rev Drug Discov

.

2015

;

14

(

1

):

7

.

doi:10.1038/nrd4531

.

8.

Topp

MS

,

Gökbuget

N

,

Stein

AS

, et al.

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

.

Lancet Oncol

.

2015

;

16

(

1

):

57

-

66

.

doi:10.1016/S1470-2045(14)71170-2

.

9.

Kantarjian

H

,

Stein

A

,

Gökbuget

N

, et al.

Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia

.

N Engl J Med

.

2017

;

376

(

9

):

836

-

847

.

doi:10.1056/NEJMoa1609783

.

10.

Locatelli

F

,

Zugmaier

G

,

Mergen

N

, et al.

Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis

.

Blood Adv

.

2022

;

6

(

3

):

1004

-

1014

.

doi:10.1182/bloodadvances.2021005579

.

11.

Alaggio

R

,

Amador

C

,

Anagnostopoulos

I

, et al.

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

.

Leukemia

.

2022

;

36

(

7

):

1720

-

1748

.

doi:10.1038/s41375-022-01620-2

.

12.

Morton

LM

,

Wang

SS

,

Devesa

SS

,

Hartge

P

,

Weisenburger

DD

,

Linet

MS

.

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

.

Blood

.

2006

;

107

(

1

):

265

-

276

.

doi:10.1182/blood-2005-06-2508

.

13.

Crump

M

,

Neelapu

SS

,

Farooq

U

, et al.

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

.

Blood

.

2017

;

130

(

16

):

1800

-

1808

.

doi:10.1182/blood-2017-03-769620

.

14.

Hübel

K

,

Ghielmini

M

,

Ladetto

M

,

Gopal

AK

.

Controversies in the treatment of follicular lymphoma

.

HemaSphere

.

2020

;

4

(

1

):

e317

.

doi:10.1097/hs9.0000000000000317

.

15.

Hutchings

M

,

Morschhauser

F

,

Iacoboni

G

, et al.

Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial

.

J Clin Oncol

.

2021

;

39

(

18

):

1959

-

1970

.

doi:10.1200/JCO.20.03175

.

16.

Dickinson

MJ

,

Carlo-Stella

C

,

Morschhauser

F

, et al.

Glofitamab for relapsed or refractory diffuse large B-cell lymphoma

.

N Engl J Med

.

2022

;

387

(

24

):

2220

-

2231

.

doi:10.1056/NEJMoa2206913

.

17.

Hutchings

M

,

Mous

R

,

Clausen

MR

, et al.

Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study

.

Lancet Lond Engl

.

2021

;

398

(

10306

):

1157

-

1169

.

doi:10.1016/S0140-6736(21)00889-8

.

18.

Thieblemont

C

,

Phillips

T

,

Ghesquieres

H

, et al.

Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial

.

J Clin Oncol

.

2023

;

41

(

12

):

2238

-

2247

.

doi:10.1200/JCO.22.01725

.

19.

Budde

LE

,

Assouline

S

,

Sehn

LH

, et al.

Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study

.

J Clin Oncol

.

2022

;

40

(

5

):

481

-

491

.

doi:10.1200/jco.21.00931

.

20.

Budde

LE

,

Sehn

LH

,

Matasar

M

, et al.

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

.

Lancet Oncol

.

2022

;

23

(

8

):

1055

-

1065

.

doi:10.1016/S1470-2045(22)00335-7

.

21.

Bartlett

NL

,

Assouline

S

,

Giri

P

, et al.

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma

.

Blood Adv

.

2023

;

7

(

17

):

4926

-

4935

.

doi:10.1182/bloodadvances.2022009260

.

22.

Bannerji

R

,

Arnason

JE

,

Advani

RH

, et al.

Odronextamab, a human CD20 × CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial

.

Lancet Haematol

.

2022

;

9

(

5

):

e327

-

e339

.

doi:10.1016/S2352-3026(22)00072-2

.

23.

Kumar

SK

,

Dispenzieri

A

,

Lacy

MQ

, et al.

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

.

Leukemia

.

2014

;

28

(

5

):

1122

-

1128

.

doi:10.1038/leu.2013.313

.

24.

Rajkumar

SV

.

Multiple myeloma: 2022 update on diagnosis, risk stratification, and management

.

Am J Hematol

.

2022

;

97

(

8

):

1086

-

1107

.

doi:10.1002/ajh.26590

.

25.

Berdeja

JG

,

Madduri

D

,

Usmani

SZ

, et al.

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

.

Lancet Lond Engl

.

2021

;

398

(

10297

):

314

-

324

.

doi:10.1016/S0140-6736(21)00933-8

.

26.

Munshi

NC

,

Anderson

LD

,

Shah

N

, et al.

Idecabtagene vicleucel in relapsed and refractory multiple myeloma

.

N Engl J Med

.

2021

;

384

(

8

):

705

-

716

.

doi:10.1056/NEJMoa2024850

.

27.

Usmani

SZ

,

Garfall

AL

,

van de Donk

NWCJ

, et al.

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

.

Lancet Lond Engl

.

2021

;

398

(

10301

):

665

-

674

.

doi:10.1016/S0140-6736(21)01338-6

.

28.

Moreau

P

,

Garfall

AL

,

van de Donk

NWCJ

, et al.

Teclistamab in relapsed or refractory multiple myeloma

.

N Engl J Med

.

2022

;

387

(

6

):

495

-

505

.

doi:10.1056/NEJMoa2203478

.

29.

Sebag

M

,

Raje

NS

,

Bahlis

NJ

, et al.

Elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients with relapsed or refractory multiple myeloma: results from MagnetisMM-1

.

Blood

.

2021

;

138

(

suppl 1

):

895

.

doi:10.1182/blood-2021-150519

.

30.

Bahlis

NJ

,

Tomasson

MH

,

Mohty

M

, et al.

Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma naïve to B-cell maturation antigen (BCMA)-directed therapies: results from cohort A of the MagnetisMM-3 study

.

Blood

.

2022

;

140

(

suppl 1

):

391

-

393

.

doi:10.1182/blood-2022-162440

.

31.

D'Souza

A

,

Shah

N

,

Rodriguez

C

, et al.

A phase I first-in-human study of ABBV-383, a B-cell maturation antigen × CD3 bispecific T-cell redirecting antibody, in patients with relapsed/refractory multiple myeloma

.

J Clin Oncol

.

2022

;

40

(

31

):

3576

-

3586

.

doi:10.1200/JCO.22.01504

.

32.

Wong

SW

,

Bar

N

,

Paris

L

, et al.

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-cell maturation antigen (BCMA) × CD3 T-cell engager (TCE), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from a phase 1 first-in-human clinical study

.

Blood

.

2022

;

140

(

suppl 1

):

400

-

402

.

doi:10.1182/blood-2022-159009

.

33.

Chari

A

,

Minnema

MC

,

Berdeja

JG

, et al.

Talquetamab, a T-cell–redirecting GPRC5D bispecific antibody for multiple myeloma

.

N Engl J Med

.

2022

;

387

(

24

):

2232

-

2244

.

doi:10.1056/NEJMoa2204591

.

34.

Carlo-Stella

C

,

Mazza

R

,

Manier

S

, et al.

RG6234, a GPRC5D × CD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed/refractory multiple myeloma (RRMM): updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study

.

Blood

.

2022

;

140

(

suppl 1

):

397

-

399

.

doi:10.1182/blood-2022-157988

.

35.

Trudel

S

,

Cohen

AD

,

Krishnan

AY

, et al.

Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study

.

Blood

.

2021

;

138

:

157

.

doi:10.1182/blood-2021-147983

.

36.

Baur

R

,

Jitschin

R

,

Kharboutli

S

, et al.

Thrombopoietin receptor agonists for acquired thrombocytopenia following anti-CD19 CAR-T-cell therapy: a case report

.

J Immunother Cancer

.

2021

;

9

(

7

):

e002721

.

doi:10.1136/jitc-2021-002721

.

37.

Hill

JA

,

Giralt

S

,

Torgerson

TR

,

Lazarus

HM

.

CAR-T—and a side order of IgG, to go?—Immunoglobulin replacement in patients receiving CAR-T cell therapy

.

Blood Rev

.

2019

;

38

(

suppl. 1

):

100596

.

doi:10.1016/j.blre.2019.100596

.

38.

Dunleavy

K

,

Tay

K

,

Wilson

WH

.

Rituximab-associated neutropenia

.

Semin Hematol

.

2010

;

47

(

2

):

180

-

186

.

doi:10.1053/j.seminhematol.2010.01.009

.

39.

Henter

J-I

,

Horne

AC

,

Aricó

M

, et al.

HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis

.

Pediatr Blood Cancer

.

2007

;

48

(

2

):

124

-

131

.

doi:10.1002/pbc.21039

.

40.

Fardet

L

,

Galicier

L

,

Lambotte

O

, et al.

Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome: score for reactive hemophagocytic syndrome

.

Arthritis Rheumatol

.

2014

;

66

(

9

):

2613

-

2620

.

doi:10.1002/art.38690

.

41.

Diaz

L

,

Jauzelon

B

,

Dillies

AC

, et al.

Hemophagocytic lymphohistiocytosis associated with immunological checkpoint inhibitors: a pharmacovigilance study

.

J Clin Med

.

2023

;

12

(

5

):

1985

.

doi:10.3390/jcm12051985

.

42.

La Rosée

P

,

Horne

AC

,

Hines

M

, et al.

Recommendations for the management of hemophagocytic lymphohistiocytosis in adults

.

Blood

.

2019

;

133

(

23

):

2465

-

2477

.

doi:10.1182/blood.2018894618

.

43.

Bukan

KB

,

Nardo-Marino

A

,

Hagdrup

C

, et al.

Haemophagocytic lymphohistiocytosis associated with leishmaniasis reactivation: a potential adverse event to anti-tumour necrosis factor-α therapy

.

Scand J Rheumatol

.

2019

;

48

(

4

):

342

-

343

.

doi:10.1080/03009742.2018.1533035

.

44.

Gynthersen

RMM

,

Hansen

MF

,

Ocias

LF

, et al.

Neoehrlichia mikurensis in Danish immunocompromised patients: a retrospective cohort study

.

Ann Clin Microbiol Antimicrob

.

2023

;

22

:

20

.

doi:10.1186/s12941-023-00571-5

.